Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Sharck Soup -- Ignore unavailable to you. Want to Upgrade?

To: Jim Spitz who wrote (36801)	10/25/2001 8:58:50 AM
From: Softechie	Respond to of 37746

Going to short BBY. It ain't be pretty next 6 months.

To: Jim Spitz who wrote (36801)	10/25/2001 8:59:02 AM
From: Jim Spitz	Read Replies (1) \| Respond to of 37746

Medtox Scientific to acquire N.J. firm for $6.2 million Terry Fiedler Star Tribune Published Oct 25 2001 St. Paul-based Medtox Scientific Inc., whose stock has shot up recently on the prospect of a possible new anthrax-testing kit, will announce today that it has completed a $6.2 million acquisition of a New Jersey testing company. The acquisition price for privately held Leadtech Corp. includes $2.5 million in cash, $2.5 million in stock and $1.2 million in seller financing, payable over two years. The deal is expected to add a minimum of 25 cents a share to earnings in 2002, the company said. Medtox lost $1.6 million on revenue of $47.1 million for the 12 months ended Sept. 30. Leadtech is a clinical laboratory with a primary business of examining lead concentrations in the blood of pediatric patients. Medtox will close Leadtech's facility, terminate its 20 employees, and absorb the work in St. Paul, where it employs about 400 people. Medtox CEO Richard Braun said the acquisition puts the company into a potentially high-growth market because recently issued federal government guidelines have encouraged more lead screening for children. Medtox provides products and services related to forensic and clinical toxicology and heavy metal analysis, but most of the interest lately has related to testing for biological agents. The company issued a news release Sept. 19 acknowledging, in response to investor inquiries, that it had previously worked with the Department of Defense on the development of test kits for the detection of several biological agents and toxins, including anthrax. Braun said that Medtox had de-emphasized such work over the past few years, but that it is examining its options given the recent anthrax incidents. Medtox stock is up more than 40 percent this month. It closed at $15.35 a share Wednesday, up $1.49. -- Terry Fiedler is at tfiedler@startribune.com . © Copyright 2001 Star Tribune. All rights reserved.